Observational Study of Everolimus in Combination With Exemestane in Postmenopausal Patients With Hormone Receptor-positive, HER 2-negative Advanced Breast Cancer

Trial Profile

Observational Study of Everolimus in Combination With Exemestane in Postmenopausal Patients With Hormone Receptor-positive, HER 2-negative Advanced Breast Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Everolimus (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 28 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top